GlassScriptPhysician profile
Mordecai A Dicker
NPI 1437169117
$17,915.69
in general payments reported to CMS, 2019-2025
45 companies · $2,711 in 2025
The $2,711 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,841 · 2020: $1,494 · 2021: $2,543 · 2022: $2,546 · 2023: $2,662 · 2024: $3,119 · 2025: $2,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,818 · Consulting Fee: $600 · Education: $33.76 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,818.21 |
| Consulting Fee | $600.00 |
| Education | $33.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,145.71 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,871.53 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,628.39 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,477.74 | 2019-2025 | Entyvio, Eohilia, Vpriv |
| Pfizer INC. | $1,042.42 | 2019-2025 | |
| Celgene Corporation | $919.97 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $633.65 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $615.67 | 2022-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $600.00 | 2024 | |
| Intercept Pharmaceuticals, INC. | $564.91 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $419.38 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $399.90 | 2019-2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $258.35 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $253.97 | 2019-2024 | |
| Redhill Biopharma INC. | $241.85 | 2020-2025 | Talicia |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $221.49 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $212.64 | 2019-2024 | Linzess |
| Allergan, INC. | $210.36 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $196.64 | 2019-2022 | |
| Genzyme Corporation | $193.89 | 2023-2025 | |
| Madrigal Pharmaceuticals | $175.83 | 2024-2025 | Resmetirom, Rezdiffra |
| Shire North American Group INC | $167.37 | 2019 | |
| Vivus LLC | $166.43 | 2019-2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $135.77 | 2024-2025 | Vowst |
| Concordia Pharmaceuticals INC. | $123.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2023 | Zeposia |
| Shionogi INC | $99.47 | 2019 | |
| Nestle Healthcare Nutrition INC. | $91.09 | 2021-2023 | |
| Daiichi Sankyo INC. | $83.86 | 2019-2022 | |
| Intra-Sana Laboratories | $83.07 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Celltrion USA INC. | $71.93 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $61.78 | 2021-2024 | Gimoti |
| Amgen INC. | $55.11 | 2023 | Amjevita |
| Conmed Corporation | $53.35 | 2025 | Conmed Biliary |
| Ipsen Biopharmaceuticals, INC | $46.70 | 2025 | Iqirvo, Bylvay |
| Ucb, INC. | $39.80 | 2019 | |
| Janssen Scientific Affairs, LLC | $35.77 | 2019 | |
| Enterra Medical, INC. | $35.72 | 2023-2025 | |
| Capsovision, INC. | $34.14 | 2024 | Capsocam Plus |
| Regeneron Healthcare Solutions, INC. | $32.80 | 2023-2025 | Dupixent |
| Medtronic, INC. | $25.77 | 2021-2024 | Gi Genius |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.43 | 2023 | Cyltezo |
| Endo Pharmaceuticals INC. | $18.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.11 | 2019 | |
| Alfasigma USA, INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,700.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mordecai Dicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.